KRAS and breast cancer: In the present study, we evaluated the hormone receptor (HR) expression, HER2 and MYC genes and their protein status, and KRAS codon 12 mutations in BC from women who underwent neoadjuvant chemotherapy, as well as their associations with clinicopathological features and chemotherapy response.